Vyne Therapeutics Inc (VYNE) Stock Price, Quote & News

Company Profile

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET i...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 775 7936

Website: vynetherapeutics.com

Address:

P.O. BOX 125, Stewartsville, United States

beppels Jul. 31 at 7:35 AM

$LFS BEPPELS WL 31.07.: - $LFS, 2.65 $, halted up in overnite, 12.5 mln float, 1110 % ctb, 0 shares to borrow, I ve called this japan gem many times as top swing, today we ll get rewarded! News are overdue, last pr was 2 weeks ago and they normally put out news every few days! Top watch today! ✅ - $NIKI, 10 $, 1.17 mln float, china bio merger from $APM.X with 51 % 13 d! ✅ - $YARW, 33 $, 600 k float, 43 $ cash per share, merger with $VYNE, climbing for days, slow and steady! ✅ Also watch $KUST, CYCU, TC and BRAI! 👀 🔥 👀

0 · Reply

Rulaxx1574 Jul. 30 at 12:56 AM

$VYNE did Yarrow dump the CEO from hell, Dumbzalski?

0 · Reply

DarvasBoxing Jul. 29 at 7:52 PM

$VYNE wen Yarrow?

1 · Reply

hiTHit Jul. 29 at 5:42 PM

$VYNE What successes has this company achieved that justify its stock price of $30?

2 · Reply

focafoca99 Jul. 28 at 9:30 PM

$VYNE merged with Yarrow Bioscience, completing a tax-free reorganization and changing its name to Yarrow Bioscience, Inc.

0 · Reply

JRR21 Jul. 28 at 7:46 PM

$VYNE there is no volume today? When will trade new yarw exvyne shares?

0 · Reply

hiTHit Jul. 28 at 3:16 PM

$VYNE In your opinion, how many reverse splits will YARROW undergo, and when will the price drop below $1?

0 · Reply

topstockalerts Jul. 28 at 12:31 AM

$VYNE buyers are treating every dip like an invitation.

1 · Reply

TwongStocks Jul. 27 at 8:34 PM

Today's reverse split results: $AMZE 1 for 8. Previous close $0.0924, $0.7392 split-adjusted Today's high $0.73 (premarket) Today's close $.3068 🔴Down 58.50% $SGLY 1 for 14 Previous close $0.2686, $3.7604 split-adjusted Today's high $4.42 Today's close $4.01 🟢Up 6.64% $STKH 1 for 3 Previous close $0.4226, $1.2678 split-adjusted Today's high $1.60 Today's close $1.35 🟢Up 6.48% $VYNE 1 for 50 Previous close $0.5090, $25.45 split-adjusted Today's high $28.56 Today's close $28.56 🟢Up 12.22% $ZNB 1 for 8 Previous close $0.2800, $2.24 split-adjusted Today's high $2.85 Today's close $2.69 🟢Up 20.09%

0 · Reply

TwongStocks Jul. 27 at 7:15 PM

$VYNE Equity Corporate Actions Alert #2026 - 527 Information Regarding the Business Combination of VYNE Therapeutics Inc. (VYNE) and Yarrow Bioscience, Inc. https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-527 The business combination of VYNE Therapeutics Inc. (VYNE) and Yarrow Bioscience, Inc. closed today, Monday, July 27, 2026. Following the completion of the business combination, the company's Common stock will undergo a name and symbol change. These actions will become effective on Tuesday, July 28, 2026. Current Company Name & Issue Type: VYNE Therapeutics Inc. Common Stock New Company Name & Issue Type: Yarrow Bioscience, Inc. Common Stock CUSIP: 92941V407 Current Symbol: VYNE New Symbol: YARW Marketplace Effective Date: July 28, 2026

0 · Reply

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease

Jul 23, 2026, 4:26 PM EDT - 8 days ago

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

Jul 21, 2026, 8:00 AM EDT - 11 days ago

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

Jul 14, 2026, 7:00 AM EDT - 18 days ago

VYNE Therapeutics Slides: Investor presentation

Jul 10, 2026, 8:00 AM EDT - 22 days ago

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

May 15, 2026, 7:00 AM EDT - 2 months ago

VYNE Therapeutics Quarterly report: Q1 2026

Feb 27, 2026, 7:00 AM EST - 5 months ago

VYNE Therapeutics Annual report: Q4 2025

Dec 17, 2025, 8:30 AM EST - 8 months ago

VYNE Therapeutics Transcript: M&A Announcement

Dec 17, 2025, 8:30 AM EST - 8 months ago

VYNE Therapeutics Press release: M&A Announcement

Dec 17, 2025, 8:00 AM EST - 8 months ago

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

Nov 12, 2025, 7:00 AM EST - 9 months ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 6, 2025, 8:00 AM EST - 9 months ago

VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 9 months ago

VYNE Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

VYNE Therapeutics Earnings release: Q3 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

Aug 14, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Earnings release: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

Jul 2, 2025, 7:45 AM EDT - 1 year ago

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Earnings release: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics Provides Update on VYN202 Program

Mar 27, 2025, 11:00 AM EDT - 1 year ago

VYNE Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 20, 2025, 8:00 AM EDT - 1 year ago

VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 6, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Mar 6, 2025, 7:00 AM EST - 1 year ago

VYNE Therapeutics Annual report: Q4 2024

Mar 6, 2025, 7:00 AM EST - 1 year ago

VYNE Therapeutics Earnings release: Q4 2024

Mar 4, 2025, 11:10 AM EST - 1 year ago

VYNE Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 20, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics to Participate in March Investor Conferences

Feb 19, 2025, 8:00 AM EST - 1 year ago

VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

Jan 6, 2025, 7:30 AM EST - 1 year ago

VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

Dec 23, 2024, 7:30 AM EST - 1 year ago

VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

Nov 12, 2024, 7:00 AM EST - 1 year ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 7, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

VYNE Therapeutics Earnings release: Q3 2024

Sep 17, 2024, 8:30 AM EDT - 2 years ago

VYNE Therapeutics Transcript: Stifel 2024 Immunology and Inflammation Virtual Summit

Sep 12, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Earnings release: Q2 2024

Jun 26, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum

Jun 13, 2024, 9:02 AM EDT - 2 years ago

VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202

May 9, 2024, 8:00 AM EDT - 2 years ago

VYNE Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Quarterly report: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Earnings release: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor

May 1, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting

Mar 19, 2024, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 1, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Registration statement: Registration Filing

Feb 29, 2024, 8:00 AM EST - 2 years ago

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update

Feb 29, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Annual report: Q4 2023

Feb 29, 2024, 7:00 AM EST - 2 years ago

VYNE Therapeutics Earnings release: Q4 2023

Feb 27, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium

Feb 21, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 10, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo

Jan 3, 2024, 8:00 AM EST - 2 years ago

VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

Nov 16, 2023, 4:03 PM EST - 2 years ago

Menlo Ventures Raises $1.35B for AI Investments

Nov 13, 2023, 7:45 AM EST - 2 years ago

VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Registration statement: Registration Filing

Nov 13, 2023, 7:00 AM EST - 2 years ago

VYNE Therapeutics Proxy statement: Proxy Filing

Nov 9, 2023, 1:30 PM EST - 2 years ago

VYNE Therapeutics Transcript: R&D Day 2023

Nov 9, 2023, 1:30 PM EST - 2 years ago

VYNE Therapeutics Slides: FY 2023

Nov 7, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023

Nov 1, 2023, 4:15 PM EDT - 2 years ago

VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million

Oct 30, 2023, 7:20 AM EDT - 2 years ago

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Oct 30, 2023, 7:05 AM EDT - 2 years ago

VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:00 AM EDT - 2 years ago

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

Sep 6, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 14, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Quarterly report: Q2 2023

Aug 14, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Earnings release: Q2 2023

May 18, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Attend BIO International Convention

May 11, 2023, 4:01 PM EDT - 3 years ago

VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Quarterly report: Q1 2023

May 11, 2023, 7:00 AM EDT - 3 years ago

VYNE Therapeutics Earnings release: Q1 2023

May 1, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions

Apr 19, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis

Mar 30, 2023, 7:45 AM EDT - 3 years ago

VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201

Mar 22, 2023, 8:00 AM EDT - 3 years ago

VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference

Mar 9, 2023, 4:01 PM EST - 3 years ago

VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update

Mar 9, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Annual report: Q4 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

VYNE Therapeutics Earnings release: Q4 2022

Feb 28, 2023, 4:00 PM EST - 3 years ago

VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 22, 2023, 8:00 AM EST - 3 years ago

VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

beppels Jul. 31 at 7:35 AM

0 · Reply

Rulaxx1574 Jul. 30 at 12:56 AM

$VYNE did Yarrow dump the CEO from hell, Dumbzalski?

0 · Reply

DarvasBoxing Jul. 29 at 7:52 PM

$VYNE wen Yarrow?

1 · Reply

hiTHit Jul. 29 at 5:42 PM

$VYNE What successes has this company achieved that justify its stock price of $30?

2 · Reply

focafoca99 Jul. 28 at 9:30 PM

$VYNE merged with Yarrow Bioscience, completing a tax-free reorganization and changing its name to Yarrow Bioscience, Inc.

0 · Reply

JRR21 Jul. 28 at 7:46 PM

$VYNE there is no volume today? When will trade new yarw exvyne shares?

0 · Reply

hiTHit Jul. 28 at 3:16 PM

$VYNE In your opinion, how many reverse splits will YARROW undergo, and when will the price drop below $1?

0 · Reply

topstockalerts Jul. 28 at 12:31 AM

$VYNE buyers are treating every dip like an invitation.

1 · Reply

TwongStocks Jul. 27 at 8:34 PM

0 · Reply

TwongStocks Jul. 27 at 7:15 PM

0 · Reply

hiTHit Jul. 27 at 4:09 PM

$VYNE Current actual price: ($0.5 ÷ 1/50 RS) ÷ 1/18 RS = $0.0005 In a few months, the sign will show 9 USD; in a few years, you’ll see a price below 1 USD…

1 · Reply

TwongStocks Jul. 27 at 11:26 AM

$AMZE $SGLY $STKH $VYNE $ZNB all have reverse splits today. Trading will resume at 9:00am ET with the RS in effect. Full details in the quoted post.

0 · Reply

DarvasBoxing Jul. 26 at 3:25 PM

$VYNE seeing different news. Doesn’t all match my account yet but it does for one. one account shows yarrow and one account shows VYNE. My dividends paid out on both.

0 · Reply

FreeBeerTomorrow Jul. 26 at 9:44 AM

$VYNE VYNE Therapeutics (VYNE) is scheduled to begin trading on a split-adjusted basis this coming Monday, July 27, 2026. Ratio: 1-for-50 reverse split. Pre-Split Outstanding Shares: ~33.4 million to 43 million shares (including equivalents). Post-Split Outstanding Shares: Approximately 670,000 to 860,000 shares following the 1-for-50 reduction. Estimated Public Float: Stripping out institutional/insider restricted holdings, the standalone tradeable float on Monday is estimated to be extremely tight—roughly 600,000 to 750,000 shares.

2 · Reply

RevenantTrading Jul. 25 at 11:29 PM

$CCHH Hot watch for next week, this can launch big with news due. CCHH very small float too! R/s tickers for Monday: $VYNE $SGLY $ZNB $STKH

0 · Reply

ManifestVisions Jul. 25 at 8:47 PM

$VYNE Reverse split next week. New float Under 1M.

0 · Reply

smithwaldJR Jul. 25 at 12:01 PM

$VYNE Should open early monday

0 · Reply

TwongStocks Jul. 24 at 8:04 PM

Five stocks with reverse splits on Monday. Four on NASDAQ and one on NYSE American (AMEX). Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Monday morning. $AMZE 1 for 8. Will reduce outstanding shares from approx 45.08m to approx 5.64m. $SGLY 1 for 14. Will reduce outstanding shares from approx 12.56m to approx 897k. $STKH 1 for 3. Will reduce outstanding ADS from approx 1.78m to approx 592k. $VYNE 1 for 50. Will reduce outstanding shares from approx 33.4m to approx 668k. $ZNB 1 for 8. Will reduce outstanding Class A shares from approx 7.76m to approx 970k.

1 · Reply

hiTHit Jul. 24 at 5:56 PM

$VYNE Hey, the 11,111 watchers here, can you keep it down a little bit?

0 · Reply

KaitM Jul. 24 at 4:46 PM

$VYNE A few years ago I invested $32,000 in VYNE, and today it's worth $199.

1 · Reply

24foryou Jul. 24 at 4:30 PM

$VYNE what happened here

2 · Reply

Invescent Jul. 24 at 4:30 PM

📉 $VYNE Top Loser #3 Move: down 41.1% 🔴 Financial Health: Weak • 0/100 🔴 Cash Flow Strength: Weak • Free cash flow -$33.12M 🔴 Profitability: Weak • Net margin -4646.1% 🟡 Valuation: Not Meaningful • P/E is not meaningful because earnings are negative; P/S is 43.53 Analysis: VYNE Therapeutics Inc. shows a weak financial profile. Not financial advice.

0 · Reply

Market Cap	19.07M
Revenue (ttm)	570,000.00
Net Income (ttm)	-26.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,645.61%
Debt to Equity Ratio	0.00

Volume	93,200
Avg Vol	19,332
Day's Range	N/A - N/A
Shares Out	668,000.00
Stochastic %K	22%
Beta	2.00
Analysts	Hold
Price Target	$2.00